Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001641172-25-018283
Filing Date
2025-07-08
Accepted
2025-07-08 21:33:02
Documents
1
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 12637
  Complete submission text file 0001641172-25-018283.txt   14115
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Issuer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address KONINGSVAREN 37 ABCOUDE P7 1391AD
Business Address
Bernards Rene (Reporting) CIK: 0001939159 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39717 | Film No.: 251112181